2024 ASCO Poster: Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay
2024 ASCO Poster: Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay
2024 AACR Poster: Novel liquid biopsy-based determination of lung cancer histology using a comprehensive epigenomic platform reveals enhancer activity as a key determinant for accurate classification
2024 AACR Poster: Novel liquid biopsy-based determination of lung cancer histology using a comprehensive epigenomic platform reveals enhancer activity as a key determinant for accurate classification
Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test
Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test
2024 AACR Poster: A novel epigenomic profiling assay reveals disease biology and therapeutic targets in gastro-esophageal cancer from 1mL of plasma
2024 AACR Poster: A novel epigenomic profiling assay reveals disease biology and therapeutic targets in gastro-esophageal cancer from 1mL of plasma
2024 AACR Poster: Comprehensive epigenomic profiling from plasma to inform therapy selection: a proof-of-concept study in cancer
2024 AACR Poster: Comprehensive epigenomic profiling from plasma to inform therapy selection: a proof-of-concept study in cancer
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024
2023 SABCS Presentation: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
2023 SABCS Presentation: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
2023 SABCS Poster: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
2023 SABCS Poster: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
Data Presented at SABCS Demonstrate the Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform to Define HER2 and ER Status in Patients With Advanced Breast Cancer
Data Presented at SABCS Demonstrate the Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform to Define HER2 and ER Status in Patients With Advanced Breast Cancer
Data Demonstrating Precede Biosciences’ Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium
Data Demonstrating Precede Biosciences’ Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium